Purchase this article with an account.
M.L. Abraham–Marin, M. Hernandez–Rojas, G. Alvarez, C.F. Cortes–Luna, V. Morales–Canton, M. Martinez, O. Ustariz, A. Solis–Vivanco, E. Reyna–Castelan, H. Quiroz–Mercado; Safety and Efficacy of Intravitreal Bevacizumab for Neovascular Age Related Macular Degeneration. Pilot Study . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5239.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the Safety and efficacy of intravitreal bevacizumab for neovascular age related macular degeneration (ARMD)
Patients with diagnosis of choroidal neovascularization associated with ARMD were injected with 1.25 mg of bevacizumab. Ophthalmologic evaluations included Best Corrected Visual acuity (BCVA) measurements, biomicroscopic and fundus examination, along with optical coherence tomography (OCT) imaging, fluorescein angiography and multifocal electroretinogram. Safety assessments were performed, along with assessments of changes from baseline in BCVA , OCT measurements, electroretinographic records, and angiographic lesion characteristics at one, three and six months postinjection.
50 patients were injected, until now 25 patients completed the one month follow–up, whose results are presented here. The mean age was 72+/– 5.3 year–old. There were no serious ocular or systemic adverse events identified. Mean BCVA was 20/216 and mean foveal thickness was 417+/– 72 micron. One month mean BCVA was 20/257 and foveal thickness was 335 +/– 78 micra. There was not statistically significant differences between BCVA and foveal thickness (p=0.57 and p=0.068 Wilcoxon signed rank test)
Intravitreal bevacizumab is safe, baseline BCVA and foveal thickness were better one month post injection but not statistically significant differences was demonstrated. Long term follow–up should be completed.
This PDF is available to Subscribers Only